ProfileGDS5678 / 1434313_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 75% 77% 75% 73% 77% 75% 75% 74% 73% 79% 77% 74% 75% 78% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.9494275
GSM967853U87-EV human glioblastoma xenograft - Control 25.2554277
GSM967854U87-EV human glioblastoma xenograft - Control 34.9693775
GSM967855U87-EV human glioblastoma xenograft - Control 44.7899373
GSM967856U87-EV human glioblastoma xenograft - Control 55.2897777
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.8144875
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.8434375
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.7684974
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.7323973
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.4981679
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.2448977
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.9140374
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.0002975
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.3394678